In This Article:
In the last week, the United States market has stayed flat, yet it has risen by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving sector.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.86% | 27.98% | ★★★★★★ |
Sarepta Therapeutics | 23.67% | 43.81% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Ardelyx | 27.19% | 66.44% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Amicus Therapeutics | 20.32% | 62.45% | ★★★★★★ |
AsiaFIN Holdings | 60.53% | 81.55% | ★★★★★★ |
Travere Therapeutics | 26.51% | 69.33% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 252 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
ADMA Biologics
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.70 billion.
Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, contributing $326.70 million, and Plasma Collection Centers, adding $3.41 million. The company is involved in the production and sale of plasma-derived biologics aimed at addressing immune deficiencies and infectious diseases on a global scale.
ADMA Biologics, recently added to the S&P 600 and 1500 indices, is demonstrating robust growth with its latest earnings revealing a significant turnaround: a net income of $32.06 million from a loss last year and revised upward revenue projections for 2024 and 2025. This surge in performance is underpinned by an aggressive R&D strategy that allocates substantial resources towards innovation—critical in the biotech sector where development cycles are long but potentially lucrative. The company's commitment to R&D, marked by expenses aligning closely with industry demands for cutting-edge biologic treatments, positions it well for sustained growth amidst forecasts of revenue increasing at 14.8% annually and earnings expected to rise by approximately 26% per year.
-
Take a closer look at ADMA Biologics' potential here in our health report.
-
Understand ADMA Biologics' track record by examining our Past report.
DigitalOcean Holdings
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DigitalOcean Holdings, Inc. operates a global cloud computing platform through its subsidiaries across North America, Europe, Asia, and other international markets with a market cap of approximately $3.84 billion.